11.30.-1
AngioDynamics Inc., an Albany, N.Y.-based maker of minimally invasive surgical devices for vascular access, surgery, peripheral vascular disease and oncology, has gained U.S. Food and Drug Administration (FDA) 510(k) clearance for its Bioflo port with Endexo technology. The device is manufactured by Navilyst Medical Inc., a subsidiary of AngioDynamics based in Marlborough, Mass.
An initial launch is expected in the company’s third quarter of fiscal year 2014, which starts Jan. 1, 2014.
Endexo technology is a permanent and non-eluting polymer designed to provide more resistance to the accumulation of platelets and thrombus. The port is designed to reduce the accumulation of catheter-related thrombus on and in the port catheter.
An initial launch is expected in the company’s third quarter of fiscal year 2014, which starts Jan. 1, 2014.
Endexo technology is a permanent and non-eluting polymer designed to provide more resistance to the accumulation of platelets and thrombus. The port is designed to reduce the accumulation of catheter-related thrombus on and in the port catheter.